Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The study objectives are to assess any changes in visual acuity and visual field observed
following the administration of RPh201 during an overall treatment period of at least 13
consecutive weeks with an option to extended the treatment phase to another 13 weeks (26
weeks total), and at the follow-up visit at 3 month after end of treatment in patients with
optic nerve neuropathy.